Chronic Hepatitis C: Current Disease Management

Immunostaining

National Digestive Diseases Information Clearinghouse
From U.S. National Institutes of Health

September 20, 1998

Immunostaining using polyclonal or monoclonal antibodies to detect HCV antigens in the liver has been reported to be useful. However, these tests are not commercially available, and even in the hands of research investigators, immunostaining detects HCV antigens in liver tissue in only 60 to 70 percent of patients with chronic hepatitis C -- largely in those with high levels of HCV in serum. This test also requires special handling of liver tissue and thus is not appropriate for routine clinical use.

Back | Next
Table of Contents

This article was provided by U.S. National Institutes of Health.

My Health Tracker

Assess Your Risk for HIV

U.S. ASO Finder

Find a Therapist

What Really Fuels the HIV/AIDS Epidemic in Black America?

Top 10 HIV/AIDS-Related Clinical Developments of 2011

Ten HIV/AIDS Stories that Defined 2011

Tennessee Senator: It's Virtually Impossible for Heterosexuals to Contract HIV From Sex: A Blog Entry by Kellee Terrell

The Culture War in the Black HIV/AIDS Movement Is Hurting Us All

More >>

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.